Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan-O-AP and LixiLan-L-CN trials.
Wenying YangXiaohui GuoFelipe LauandLingyu LiHexin FangQin DuLei KangPublished in: Diabetes, obesity & metabolism (2024)
iGlarLixi showed consistent efficacy and safety across all age and disease duration subgroups in Asian people with uncontrolled T2D, including older individuals and those with longstanding disease.